The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The survival impact of increasing access to CAR T-cell therapy for R/R DLBCL: an analysis in the US
Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, discusses an analysis exploring the survival impact of not receiving CAR T-cell therapy when eligible in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US). Dr Locke notes that the current number of patients receiving CAR T-cell therapy is inadequate and that increasing access to this treatment could have a big impact. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We did a really cool analysis. We took a look at the numbers of patients with diffuse large B-cell lymphoma, and we applied the NCCN guidelines to that population of patients. And looking at the guidelines, we estimated that over 8,000 of those patients could be refractory and potentially eligible for CAR T-cell therapy. And so we did some sort of statistical analysis to look at whether patients who are eligible for CAR-T are not getting it and what the impact of that is...
We did a really cool analysis. We took a look at the numbers of patients with diffuse large B-cell lymphoma, and we applied the NCCN guidelines to that population of patients. And looking at the guidelines, we estimated that over 8,000 of those patients could be refractory and potentially eligible for CAR T-cell therapy. And so we did some sort of statistical analysis to look at whether patients who are eligible for CAR-T are not getting it and what the impact of that is. And in fact, if we look at the number of people with refractory large B-cell lymphoma that are getting CAR-T, it’s woefully inadequate. And so we can take a look at the numbers and we can say, look, if they should be getting it based upon expert guidelines and expert opinion, how many more lives could be saved? And the reality is for patients who are not getting this therapy, who could benefit from it, we could potentially save 25 months of life for each patient who’s not getting it. And in fact, we could save almost 800 life years per year by giving a higher number of patients CAR T-cell therapy who are eligible for it. So it’s really important that we increase access for these patients, get the word out, and patients get referred for CAR T-cell therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
